- Home
- WSO vs MRNA Comparison
WSO vs MRNA Comparison
Compare WSO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSO
- MRNA
- Stock Information
- Founded
- WSO 1945
- MRNA 2010
- Country
- WSO United States
- MRNA United States
- Employees
- WSO N/A
- MRNA N/A
- Industry
- WSO Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSO Consumer Discretionary
- MRNA Health Care
- Exchange
- WSO Nasdaq
- MRNA Nasdaq
- Market Cap
- WSO 19.1B
- MRNA 16.0B
- IPO Year
- WSO N/A
- MRNA 2018
- Fundamental
- Price
- WSO $497.85
- MRNA $35.53
- Analyst Decision
- WSO Buy
- MRNA Hold
- Analyst Count
- WSO 4
- MRNA 20
- Target Price
- WSO $495.00
- MRNA $59.65
- AVG Volume (30 Days)
- WSO 249.4K
- MRNA 13.6M
- Earning Date
- WSO 02-18-2025
- MRNA 02-14-2025
- Dividend Yield
- WSO 2.18%
- MRNA N/A
- EPS Growth
- WSO N/A
- MRNA N/A
- EPS
- WSO 13.30
- MRNA N/A
- Revenue
- WSO $7,618,317,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- WSO $4.49
- MRNA N/A
- Revenue Next Year
- WSO $6.36
- MRNA $22.19
- P/E Ratio
- WSO $37.31
- MRNA N/A
- Revenue Growth
- WSO 4.59
- MRNA N/A
- 52 Week Low
- WSO $380.58
- MRNA $29.25
- 52 Week High
- WSO $571.42
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- WSO 53.76
- MRNA 48.60
- Support Level
- WSO $461.45
- MRNA $32.78
- Resistance Level
- WSO $535.40
- MRNA $36.98
- Average True Range (ATR)
- WSO 12.39
- MRNA 2.50
- MACD
- WSO 4.47
- MRNA 0.30
- Stochastic Oscillator
- WSO 49.37
- MRNA 66.81
About WSO Watsco Inc.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of 2023 revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.